Cell Source, Inc. (CLCS)
OTCMKTS: CLCS · Delayed Price · USD
0.311
-0.269 (-46.38%)
Mar 28, 2024, 3:25 PM EDT - Market closed
Company Description
Cell Source, Inc., a biotechnology company, develops cell therapy treatments based on the management of immune tolerance.
The company's lead product is the Veto Cell immune system management technology, which is an immune tolerance biotechnology that enables the selective blocking of immune responses.
Its Veto Cell technology is used in various applications, including treatment of lymphoma, leukemia, and multiple myeloma through facilitation of the stem cell transplantation acceptance, as well as treatment of end stage kidney disease and other non-malignant organ diseases, and various cancers and non-malignant diseases.
Cell Source, Inc. was incorporated in 2012 and is headquartered in New York, New York.
Cell Source, Inc.
Country | NY |
Founded | 2011 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 1 |
CEO | Itamar Shimrat |
Contact Details
Address: 57 West 57th Street, Suite 400 New York, New York 10019 United States | |
Phone | 646-612-7554 |
Website | cell-source.com |
Stock Details
Ticker Symbol | CLCS |
Exchange | OTCMKTS |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001569340 |
CUSIP Number | 15114L104 |
ISIN Number | US15114L1044 |
Employer ID | 32-0379665 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. Dennis M. Brown B.Sc., M.A., Ph.D. | Executive Chairman |
Itamar Shimrat | Chief Executive Officer, President and Chief Financial Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Nov 9, 2023 | 10-Q | Quarterly Report |
Oct 6, 2023 | D | Notice of Exempt Offering of Securities |
Sep 19, 2023 | 10-Q | Quarterly Report |
Aug 23, 2023 | 10-Q | Quarterly Report |
Aug 15, 2023 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB |
Aug 8, 2023 | 10-K | Annual Report |
May 16, 2023 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB |
Mar 31, 2023 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |
Dec 8, 2022 | 10-Q | Quarterly Report |
Dec 2, 2022 | 10-Q | Quarterly Report |